BEBT-908

BEBT-908

   BEBT-908 is an HDAC/PI3K dual inhibitor with a first-in-class structure. It can attack and disrupt both HDAC and PI3K signaling pathways simultaneously with extremely high potency. In preclinical studies, it demonstrated impressive activities against lymphoma, myeloma, and leukemia, causing tumor regression in animal models. BEBT-908 is currently undergoing phase I clinical trial in China.  As the number of newly diagnosed leukemia, myeloma, and chronic lymphocytic leukemia patients annually exceeds 100, 000 in China, we believe BEBT-908 has great potential as an anti-cancer drug.